Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort

Developmental Medicine & Child Neurology (Impact Factor: 3.29). 08/2008; 50(9):672 - 677. DOI: 10.1111/j.1469-8749.2008.03042.x

ABSTRACT The aim of this study was to determine the prevalence of autistic spectrum disorder (ASD) within a large representative population sample: the Avon Longitudinal Study of Parents and Children (ALSPAC). Cases of ASD were identified from the clinical notes of children in the ALSPAC with a suspected developmental disorder and from the Pupil Level Annual Schools Census (PLASC) for England in 2003. Seventy-one cases of ASD diagnosed after a multidisciplinary assessment were identified from health records. There were an additional 15 cases from PLASC data in which ASD was mentioned as a principal difficulty, thus giving a total of 86 children diagnosed by the age of 11 years. Prevalence of ASD per 10 000 population at 11 years was 51.1 for those with a multi-professional diagnosis, and 61.9 if cases from education were included, made up of 21.6 for childhood autism, 10.8 for atypical autism, 16.6 for Asperger syndrome, and 13.0 for unspecified ASD. The male:female ratio was 6.8:1. Median age at diagnosis ranged from 45 months in childhood autism to 116 months in Asperger syndrome. A comorbid developmental disorder was recorded in 33.8% of cases, including learning disability† in 14.7%, epilepsy in 10.3%, and mixed developmental disorder in 4.4%. We conclude that the prevalence of ASD diagnosed at 11 years in a UK representative population-based sample is at least 51.1/10 000.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: We analyzed data from the Israeli National Insurance Institute (NII). Autism Spectrum Disorder (ASD) incidence was calculated for all children born in Israel 1992-2009, and by population groups. Overall, 9,109 ASD cases among 2,431,649 children were identified. ASD cumulative incidence by age 8 years increased 10-fold during 2000-2011, from 0.49 % to 0.49 %, while other child disabilities in NII increased only 1.65-fold. There was a consistent increase in ASD incidence with advancing birth cohorts born 1992-2004, stabilizing among those born 2005-2009. ASD rates among Israeli Arabs were substantially lower, and increased about 10 years later than the general population. The findings suggest a role for ASD awareness, accessing of the government benefit, or the way the concept of ASD is perceived.
    Journal of Autism and Developmental Disorders 10/2014; 45(4). DOI:10.1007/s10803-014-2262-z · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Non-specific perinatal risk factors have been shown to be associated with the development of autism spectrum disorder (ASD); however, term at-risk infants, as a distinct population, are underrepresented in the literature. This study examines the incidence and neonatal risk factors for ASD in term neonatal intensive care unit (NICU) survivors. Methods Retrospective analysis from a single university-practice database of neonates admitted to the NICU and followed by a single paediatric neurologist. Term infants (≥ 37 weeks), born between 1991 and 2011 with at least two years (or one year if found to be neurologically normal) of follow-up were included. Principle outcomes were: ASD, cerebral palsy (CP), global developmental delay (GDD), and epilepsy. Results 180 infants were included from a database of 564 neonates. Twelve (6.6%) developed ASD, 53 (29.4%) CP, 77 (42.7%) GDD and 47 (26.1%) epilepsy. Seventy-one (39.4%) developed no adverse outcomes. Nine patients with ASD (75%) were diagnosed with at least one other adverse outcome. No neonatal or perinatal variables were found to be significantly associated with later ASD. Conclusions In term NICU survivors, ASD occurs with a greater frequency than in the general population and often develops alongside comorbid conditions. This highlights the importance of screening term NICU survivors for ASD, particularly when comorbidities are present.
    Pediatric Neurology 07/2014; 51(6). DOI:10.1016/j.pediatrneurol.2014.07.009 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper extensively and comprehensively reviews the literature on epidemiology of autism focusing on the prevalence rates of Autistic Disorder (AD) and Autism Spectrum Disorder (ASD), and the potential negative impact of DSM-5 ASD on future ASD prevalence studies. Between 1966 and 2013, there are 72 published prevalence studies of AD and 61 published studies of ASD. The AD has a broad range of prevalence rates and has shown a trend of increasing rates over time. But there are also some evidences showing that the increase seems to have leveled off. The current prevalence of AD is estimated in the range of 10–30 per 10,000 people (i.e., 1 in 1000 to 1 in 333). The ASD also has a wide range of prevalence rates with a median rate of 69.5 per 10,000 people (1 in 144). When the prevalence rates are subdivided into several sub-ranges (e.g., 10–20, 20–40, etc. per 10,000), it is difficult to pick a particular sub-range to represent the prevalence of ASD. The present review notes that several recent studies comparing the utility of DSM-IV/DSM-IV-TR ASD and the DSM-5 ASD have reported that about 9–54% of DSM-IV ASD cases do not qualify for the DSM-5 ASD. Suggestions of research designs for future ASD prevalence studies are offered.
    Research in Autism Spectrum Disorders 11/2014; 8(11):1454–1470. DOI:10.1016/j.rasd.2014.07.016 · 2.96 Impact Factor